Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Journal of the Society for Gynecologic Investigation
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Madsen, K. M.
Right arrow Articles by Thaete,, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Madsen, K. M.
Right arrow Articles by Neerhof, M. G.
Right arrow Articles by Wessale, J. L.
Right arrow Articles by Thaete,, L. G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Influence of ETB Receptor Antagonism on Pregnancy Outcome in Rats

Kevin M. Madsen, MD

Mark G. Neerhof, DO

Jerry L. Wessale, PhD

Larry G. Thaete,, PhD

Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Northwestern University Medical School, Evanston Northwestern Healthcare, Evanston; Pharmaceutical Discovery, Abbott Laboratories, Abbott Park, Illinois

Objective: To determine the effect of endothelin-B (ETB)-selective receptor antagonism on pregnancy outcome in normal rats.

Methods: ETB receptor antagonist (A-192621; 5.0, 10.0, and 15.0 mg/kg per day) or vehicle was infused subcutaneously for 7 days by osmotic pump. Infusion was begun on day 14 of a 22-day gestation. Nonpregnant animals were treated similarly, and blood pressure (BP) responses and plasma antagonist levels were compared to those in pregnant animals. Mean arterial pressure (MAP) was measured on days 1, 4, and 7 of the infusion. Plasma ETB antagonist levels were measured on day 7 of infusion. On gestational day 21, fetal and placental weights and viability were evaluated at hysterotomy. Data were analyzed by analysis of variance and are presented at mean ± standard error of the mean.

Results: Fetal and placental weights were significantly lower at doses of 10 and 15 mg/kg per day of the ETB antagonist compared with vehicle-treated controls (P < .001); these effects were less severe at 15 than at 10 mg/kg per day despite a fourfold higher plasma level of antagonist. Mean arterial pressure was significantly higher at 10 and 15 mg/kg per day compared with controls, but only on infusion day 1 (P < .05). In contrast, MAPs for nonpregnant rats were elevated throughout the infusion at all doses of the ETB antagonist (P < .05).

Conclusions: ETB receptor antagonism inhibited fetal growth and increased maternal MAP in a dose-dependent manner, although the effect on BP was not sustained in pregnant animals. ETB receptor antagonism is detrimental to pregnancy outcome in the rat.

Key Words: Intrauterine growth restriction • endothelin receptor antagonism • rat • hypertension • pregnancy

Journal of the Society for Gynecologic Investigation, Vol. 8, No. 4, 239-244 (2001)
DOI: 10.1177/107155760100800409
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?